CeriBell, Inc. (CBLL)
CBLLNASDAQ-GSBiotechnology: Electromedical & Electrotherapeutic Apparatus
$27.48
-0.1200 (-0.43%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.07bn
- P/E
- –
- EPS, last 4 quarters
- $-1.87
- Dividend yield
- –
- Day range
- –
- 52-week range
- $11.42 to $28.89
- Average volume
- 462.9k
- Previous close
- $27.60
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $31.20, +13.5% from here
Earnings
next estimate $-0.5000Next report
Dec 2025
+16.3%
Mar 2026
-33.3%
Jun 2026
-13.3%
Sep 2026
+4.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $24.78m | $26.49m | $28.10m | $29.34m |
| Gross profit | $21.64m | $23.12m | $25.94m | $26.34m |
| Operating income | -$14.60m | -$20.75m | -$19.98m | -$20.55m |
| Net income | -$13.53m | -$19.74m | -$19.27m | -$21.35m |
Last four quarters: revenue $108.72m, margin -68.0%, free cash flow -$56.43m
News
8 latest- CeriBell Consensus Price Target Raised 10.5% to $32.20Fintel · 1 day ago
- CeriBell (CBLL) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- CeriBell Posts Higher Q3 Loss Of $21 Mln With New Launch Expenses; Stock Down RTTNews · 7 days ago
- CeriBell Q3 Earnings Call HighlightsMarketBeat · Nov 3, 2026
- CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 3, 2026
- Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key MetricsZacks · Nov 3, 2026
- CeriBell Launches Delirium Detection System To ICU Brain Monitoring Platform With Medicare Backing RTTNews · Nov 3, 2026
- Monday's ETF Movers: IHI, REMX BNK Invest · Oct 12, 2026
The company
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel point-of-care electroencephalography ('EEG') platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence ('AI')-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and monitoring delirium in intensive care units and emergency rooms across the U.S . Ceribell is headquartered in Sunnyvale, California .
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- ceribell.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.